Comparative Pharmacology
Head-to-head clinical analysis: KOGLUCOID versus VIMIZIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KOGLUCOID versus VIMIZIM.
KOGLUCOID vs VIMIZIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KOGLUCOID (velaglucerase alfa) is a recombinant form of human glucocerebrosidase, which catalyzes the hydrolysis of glucocerebroside to glucose and ceramide. It replaces the deficient enzyme in patients with Gaucher disease, reducing accumulation of glucocerebroside in macrophages.
VIMIZIM (elosulfase alfa) is a recombinant human N-acetylgalactosamine-6-sulfatase that hydrolyzes the sulfate ester bond at position 6 of N-acetylgalactosamine in chondroitin sulfate and keratan sulfate, thereby reducing glycosaminoglycan (GAG) accumulation in patients with Morquio A syndrome (mucopolysaccharidosis IVA).
60 U/kg intravenously over 4 hours every 2 weeks.
2 mg/kg administered intravenously once weekly over approximately 4 hours. Pretreat with antihistamines and antipyretics 30-60 minutes prior to infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 15-30 minutes (range 11-35 min) in plasma after IV infusion. Short half-life necessitates frequent dosing (every 2 weeks). This reflects rapid clearance via receptor-mediated uptake into macrophages.
Terminal elimination half-life approximately 9.8 days (range 7.7–13.8 days) in patients with mucopolysaccharidosis VI (MPS VI). Long half-life supports weekly intravenous dosing.
KOGLUCOID (velaglucerase alfa) is a recombinant human glucocerebrosidase used for Gaucher disease. It is a protein therapeutic; elimination occurs via catabolism (proteolysis) to small peptides and amino acids. No significant renal or biliary excretion of intact drug. <1% excreted unchanged in urine.
Primarily renal. No specific data on biliary or fecal elimination; as a recombinant enzyme, likely catabolized to peptides and amino acids, with renal excretion of metabolites.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy